The Netherlands is implementing a new strategy to combat shingles, a painful condition that primarily affects older adults and those with weakened immune systems. Starting in 2027, individuals turning 60 will be offered a free shingles vaccination, a move intended to reduce the incidence of the disease and its debilitating complications. However, this targeted approach means that those already aged 60 and over will not be eligible for the free vaccine, a decision driven by budgetary constraints.
Shingles, caused by the reactivation of the varicella-zoster virus – the same virus that causes chickenpox – manifests as a painful rash, often accompanied by blistering. While not life-threatening, the pain associated with shingles can be severe and long-lasting, sometimes leading to postherpetic neuralgia, a chronic nerve pain condition. The introduction of a vaccination program aims to alleviate this burden, but the limited scope has sparked debate about equitable access.
The decision to focus on those turning 60 stems from a cost-benefit analysis. The vaccine, Shingrix, is highly effective, preventing approximately 90% of shingles cases in adults aged 50 and older, and reducing the risk of long-term pain by the same amount, even up to six to ten years after vaccination according to the National Institute for Public Health and the Environment (RIVM). However, a complete two-dose course costs around €400 as reported by NOS News, making a nationwide program for the over-60s financially unsustainable. With over 5 million people aged 60 and above in the Netherlands, the cost would be prohibitive.
Demissionary State Secretary for Prevention, Judith Tielen, explained that the chosen age group represents the most cost-effective approach to maximizing health benefits. “With a choice for the age of 60, the most cases of shingles are ultimately prevented,” she stated in a letter to the Dutch Parliament according to NOS News. The government has allocated €47 million annually starting in 2027, increasing to €53 million per year from 2030, to fund the program through 2039.
Who is Eligible for the Shingles Vaccine?
While the national program targets those turning 60, the shingles vaccine is also recommended for individuals with compromised immune systems. This includes people who have undergone stem cell or organ transplants, those undergoing cancer treatment that suppresses the immune system, individuals living with HIV, and those being treated with immunosuppressive medications as outlined by the RIVM. Even those who have previously had shingles can benefit from vaccination to prevent future outbreaks.
For individuals who do not qualify for the free vaccination program, the option remains to purchase the vaccine privately. However, the significant cost – approximately €400 for the two required doses – presents a financial barrier for many.
The Importance of Vaccination
The RIVM recommends Shingrix over the older Zostavax vaccine, citing its superior efficacy and longer-lasting protection. Shingrix prevents nine out of ten cases of shingles and reduces the risk of persistent pain according to RIVM research. The vaccination schedule involves two injections, spaced between two and six months apart.
The GGD GHOR Nederland, the association of public health services in the Netherlands, supports the Health Council’s advice to vaccinate people aged 60 and over against shingles as stated on their website.
While the decision to limit the free vaccination program to those turning 60 is acknowledged as a difficult one, officials maintain We see a necessary step to ensure the most effective use of available resources. The program is expected to vaccinate at least 150,000 people annually according to NOS News, significantly reducing the incidence of shingles and its associated complications.
Looking ahead, the success of the program will be closely monitored to assess its impact on shingles rates and the potential for future expansion. Continued evaluation of vaccine costs and efficacy will be crucial in determining whether broader access can be achieved in the years to come.
Have your say: What are your thoughts on the current shingles vaccination program? Share your comments below.
Disclaimer: This article provides informational content and should not be considered medical advice. Please consult with a healthcare professional for personalized guidance on vaccinations and health concerns.
